Key MessageIn recurring stage III colon cancer patients, microsatellite instable (MSI) was associated with a better survival and *BRAF* mutation with a worse one. In the era of immunotherapies for MSI and combination of targeted therapies for *BRAF* mutant mCRCs, having a better picture of the respective prognostic value of each of these two molecular markers may help to better design future clinical trials and tailor patients individual treatment.Alt-text: Unlabelled Box

Introduction {#s0015}
============

Surgery alone or combined with adjuvant chemotherapy remains the cornerstone of treatment of non-metastatic colorectal cancer (CRC) \[[@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045]\]. Chromosomal instability and microsatellite instability (MSI) are distinct, well-described pathways of colorectal carcinogenesis that confer a different prognosis \[[@bb0050]\]. MSI/deficient DNA mismatch repair (MSI/dMMR) is considered a favorable prognostic factor in non-metastatic patients (stage I to III) tumors \[[@bb0050]\]; however, its prognostic role in metastatic CRC (mCRC) patients remains controversial.

A recent meta-analysis suggested that MSI/dMMR is a poor prognostic factor in patients eligible for the first-line treatment of non-resectable mCRC \[[@bb0055]\]. In this analysis, however, number of patients in each subgroup were limited which precluded definitive conclusions. Moreover, MSI/dMMR CRCs are often mutated for *BRAF^V600E^*, an established poor prognostic factor in mCRC that complicates the picture.

Clinical trials testing immunotherapy for MSI/dMMR mCRC patients, and targeted treatment of *BRAF^V600E^* mCRC patients, have yielded promising results. Having a clearer picture of the prognosis of each of these molecular subgroups is important given that approaches to their treatment is rapidly changing.

Among patients treated in seven phase III trials of adjuvant chemotherapy, we analyzed overall survival after disease recurrence in relationship to MMR and *BRAF^V600E^* status.

Materials and methods {#s0020}
=====================

Study population and patients characteristics {#s0025}
---------------------------------------------

Histologically proven stage III colon adenocarcinomas had been completely resected from all eligible patients in a pooled analysis of seven adjuvant trials: MOSAIC, NCCTG NO147, PETACC8, PETACC3, NSABP C07, NSABP C08, and AVANT \[[@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045]\]. Patients were randomly assigned to receive 6 months of different regimens with fluoropyrimidines alone or with CPT11, or with oxaliplatin ± targeted therapy (bevacizumab, cetuximab), with regular monitoring, as described previously. Main results of all trials have been previously published. Among the 16,120 randomized patients, 4861 recurred and patients who had consented to translational research were tested for *BRAF^V600E^* and MMR status.

DNA extraction and BRAF mutation analysis {#s0030}
-----------------------------------------

Tumor samples were prospectively banked in all trials except for MOSAIC for which tumor banking was done retrospectively.

Tumor DNA was extracted from FFPE tissues containing more than 50% of tumor cells using DNA extraction kits. Molecular analysis was carried out retrospectively. *BRAF^V600E^* (c.1799T\>A/p.V600E) was detected by allele specific real-time PCR. All assays were alteration-specific and robustly detect ≥10% of mutated alleles for all mutations tested.

Microsatellite status determination {#s0035}
-----------------------------------

Mismatch repair (MMR) tumor status was determined by immunohistochemistry, or by MSI testing. MSI tumors were defined as showing loss of the expression of one or more MMR proteins or exhibiting high-level MSI by PCR testing. Microsatellite stable (MSS) tumors had normal MMR protein expression and/or MSS or low-level MSI status.

Statistical analyses {#s0040}
--------------------

The primary outcome is survival after recurrence (SAR), defined as the time from recurrence to death due to all causes. Due to potential confounding and heterogeneities across studies, all analyses were based on multivariable models which adjusted for clinicopathologic variables, time to recurrence, and stratified per treatment groups within each study. The distribution of SAR between patient subgroups by biomarkers was estimated based on direct adjusted survival curves \[[@bb0060], [@bb0065]\]. Models were adjusted for age, sex, performance score, initial T/N stage, histologic grade, time from initial treatment to recurrence, primary tumor site and biomarkers when applicable. Two-sided P values are reported; P \<.05 was considered statistically significant and was not adjusted for multiple comparisons. Analyses were carried out using SAS software (version 9.4; SAS Institute Inc).

Results {#s0045}
=======

Study population {#s0050}
----------------

Among the 4861 patients randomized in the seven trials with disease recurrence, 2630 had consented to translational research with available material and thus, had complete data for *BRAF^V600E^*and MMR status (see CONSORT diagram, [supplementary Figure S1](#ec0010){ref-type="fig"}, available at *Annals of Oncology* online). In the CONSORT diagram ([supplementary Figure S1](#ec0010){ref-type="fig"}, available at *Annals of Oncology* online) the 2230 patients excluded due to not having MSI or *BRAF* results are mixing patients for which no translational informed consent was available and patients for which *BRAF* or MSI status was not carried out due to inadequate materials or testings.mdz208_Supplementary_Datamdz208_Supplementary_Datamdz208_Supplementary_Data

Demographic and clinical characteristics of the patients in the molecular study (*n* = 2630) and the others (*n* = 2231) are summarized in [supplementary Table S1](#ec0010){ref-type="fig"}, available at *Annals of Oncology* online.

Among the 2630 patients with MMR and *BRAF* data, 307 (11.7%) tumors harbored *BRAF^V600E^* and 271 (10.3%) were MSI/dMMR. Among MSI/dMMR tumors, 91 (33.6%) harbored *BRAF^V600E^,* and among *BRAF^V600E^* mutants, 91 (29.6%) were MSI/dMMR.

Clinical and pathological patients' characteristics per study are summarized in [supplementary Table S2](#ec0010){ref-type="fig"}, available at *Annals of Oncology* online.

Demographic and clinical characteristics according to MSI/dMMR and BRAF status {#s0055}
------------------------------------------------------------------------------

Patients with tumor recurrence and MSI/dMMR were more likely to be females and to have had a proximal primary tumor that was poorly differentiated, pT4/N2, *BRAF^V600E^*, had more lymph nodes examined, and were less frequently *KRAS* mutated ([supplementary Table S3](#ec0010){ref-type="fig"}, available at *Annals of Oncology* online).

Patients with *BRAF^V600E^* tumors were more frequently females and to have had a proximal primary tumor that was poorly differentiated, pT4/N2, MSI/dMMR, and non *KRAS* mutated ([supplementary Table S4](#ec0010){ref-type="fig"}, available at *Annals of Oncology* online).

Outcome in different molecular subgroups {#s0060}
----------------------------------------

In the overall population with recurrence (*N* = 4861), median follow-up was 77.3 months (95% confidence interval \[CI\] 75.4--80.5) and median SAR was 23.1 months (95% CI 22.3--23.9).

A single multivariable Cox model was fitted with variables listed in Tables [1](#t0010){ref-type="table"} and [2](#t0015){ref-type="table"} (clinic-pathologic variables plus MSI/MMR and BRAF variables). To better outline our results, the HRs associated with MSI/MMR and BRAF are reported in [Table 2](#t0015){ref-type="table"} (first two sections) and the median SAR and HRs are only reported for MMR and BRAF variables. In multivariable analysis adjusted for MSI/dMMR and *BRAF^V600E^* status, factors associated with a poor SAR were as follows: older age, male gender, T4/N2, proximal primary tumor location, poor differentiation, and early recurrence (by 1-year increase) ([Table 1](#t0010){ref-type="table"}).Table 1Multivariable associations between patient demographics and disease characteristics with survival after recurrence (SAR), adjusting for biomarkers (MSI/MMR and BRAF)[a](#tf0010){ref-type="table-fn"}Table 1Events/totalHazard ratio (95% CI)*P*-value[b](#tf0015){ref-type="table-fn"}Age, 5-year increase1428/19871.04 (1.01--1.07)0.0057Gender Female614/8600.88 (0.79--0.98)0.0218 Male814/1127ReferencePrimary tumor location Distal657/10260.64 (0.57--0.72)\<0.0001 Proximal771/961ReferenceT-stage T1/260/104Reference T31048/14691.20 (0.92--1.57)0.1746 T4320/4141.45 (1.09--1.92)0.0102N-Stage N1583/890Reference N2845/10971.36 (1.22--1.51)\<0.0001Histologic grade Low grade (grade 1--2)1022/1482Reference High grade (grade 3/4)406/5051.36 (1.20--1.53)\<0.0001KRAS status MT597/7911.21 (1.07--1.36)0.0023 WT831/1196ReferencePerformance score 01077/1519Reference 1341/4571.18 (1.04--1.34)0.0089 210/113.54 (1.87--6.70)0.0001Time-to-recurrence, 1-year increase1428/19870.87 (0.82--0.91)\<0.0001[^1][^2][^3]Table 2Multivariable associations between patient biomarkers (MMR and BRAF status) with survival after recurrence (SAR), adjusting for demographics and disease characteristics[a](#tf0020){ref-type="table-fn"}Table 2SARAdjusted survivalEvent/totalMedian (95% CI)^KM^Hazard ratio (95% CI)^Cox^*P*-valueMMR status0.0290[b](#tf0025){ref-type="table-fn"} dMMR162/2202.2 (1.9--2.7)0.82 (0.69--0.98) pMMR1266/17672.0 (1.9--2.2)ReferenceBRAF status\<0.0001[b](#tf0025){ref-type="table-fn"} MT219/2441.2 (0.9--1.4)2.06 (1.73--2.46) WT1209/17432.2 (2.1--2.4)ReferencedMMR patients only BRAF status\<0.0001[b](#tf0025){ref-type="table-fn"} MT64/770.8 (0.5--1.1)2.65 (1.67--4.21) WT98/1431.9 (1.7--2.5)ReferencepMMR patients only BRAF status\<0.0001[b](#tf0025){ref-type="table-fn"} MT155/1671.3 (0.9--1.5)2.12 (1.74--2.58) WT1111/16002.3 (2.2--2.4)ReferenceBRAF WT patients only MMR status0.1030[b](#tf0025){ref-type="table-fn"} dMMR98/1432.4 (1.9--3.5)0.84 (0.67--1.04) pMMR1111/16002.3 (2.2--2.4)ReferenceBRAF MT patients only MMR status0.4299[b](#tf0025){ref-type="table-fn"} dMMR64/770.8 (0.7--1.1)0.88 (0.63--1.22) pMMR155/1670.9 (0.8--1.2)ReferenceAdjuvant FP + oxaliplatin patients only MMR status0.0476[b](#tf0025){ref-type="table-fn"} dMMR66/922.5 (1.8--4.6)0.76 (0.58--1.00) pMMR537/7712.0 (1.9--2.2)Reference[^4][^5][^6][^7]

Multivariable analysis revealed that patients with MSI/dMMR tumors had significantly better SAR than did patients with MSS/proficient (p)MMR tumors ([Table 2](#t0015){ref-type="table"}, [Figure 1](#f0010){ref-type="fig"}). This was also observed among patients treated with standard adjuvant fluoropyrimidine+oxaliplatin only. The same trends were observed when analyzing patients with MSI/dMMR tumors lacking *BRAF^V600E^* and mutant subgroups separately, without achieving statistical significance ([Table 2](#t0015){ref-type="table"}).Figure 1Survival after recurrence in patients with resected stage III colon cancer according to the MMR and *BRAF^V600E^*mutational status, adjusted for age, gender, PS, T-stage, N-stage, primary, grade, KRAS, recurrence years.Figure 1

As previously described, poor SAR was observed in *BRAF^V600E^* versus nonmutated patients and this was also found in the subgroup of MSI/dMMR patients ([Table 2](#t0015){ref-type="table"}).

Discussion {#s0065}
==========

We report the largest study examining the role of MMR and *BRAF^V600E^*status among patients (*n* = 2630) with colon cancer recurrence following surgery and adjuvant chemotherapy. Among recurrent colon cancers, MSI/dMMR and *BRAF^V600E^*each had a low prevalence (around 10%). Whereas *BRAF^V600E^*indicates a poor prognosis, we found that MSI/dMMR status was associated with a better SAR. Moreover, the association of *BRAF^V600E^*with poor prognosis was found in both MSI/dMMR and MSS/pMMR patients. Most studies report a poor prognostic value of *BRAF^V600E^* in CRC, and in MSI/dMMR patients in the metastatic setting \[[@bb0055]\]. The general explanation for the poor prognosis of MSI/dMMR tumors in the metastatic setting, as compared with their favorable prognosis in the adjuvant setting, is based on possible immunoescape and immuno-editing processes with strong immune infiltration \[[@bb0070]\]. MSI/dMMR tumors that recur appear to have escaped immune surveillance by diverse cellular and molecular processes, and thus tend to be more aggressive. Marissa et al. demonstrated recently that immune checkpoint expression cancels the prognostic relevance of tumor-infiltrating T cells in highly immunogenic colon tumors and predicts a poor outcome in MSI CRC patients \[[@bb0075]\]. Another explanation is the overlap between MSI and the poor prognostic *BRAFV600E* mutations.

This work has however some limitations including the fact that only 54% of recurring patients were analyzed due to missing patients consents of inadequate *BRAF* and MMR testing. Moreover, in contrast to prior reports, all patients had subsequent recurrent disease and were treated with previous adjuvant therapy. This may explain why our results differ compared with studies of patients with non-resectable mCRC eligible for a first-line trial \[[@bb0055]\]. However, a recent study of mCRC patients enrolled in a first-line study (CALGB/SWOG 80405) found that MMR status was not a poor prognostic factor \[[@bb0080]\].

In summary, our data demonstrate in a large cohort of MSI/dMMR patients with recurrence and before the era of immuno-oncologic treatments, that MSI/dMMR (versus MSS/pMMR) status is associated with a longer survival. Furthermore, *BRAF^V600E^* was observed to be a poor prognostic factor for both MSI/dMMR and MSS/pMMR patients. As both MSI and *BRAF* status influence recurring colon cancer patients' outcome, these factors should be used to stratify patients in future clinical trials dedicated to MSI or BRAF mutant mCRC.
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[^1]: MSI, microsatellite instable; MMR, mismatch repair; BRAF; CI, confidence interval; KRAS; MT, mutated; WT, wild type.

[^2]: A single multivariable Cox model was fitted with variables listed in the table, plus MSI/MMR and BRAF variables. The HRs associated with MSI/MMR and BRAF are reported in [Table 2](#t0015){ref-type="table"} (first two sections).

[^3]: Stratified covariate Wald *P*-value.

[^4]: ^KM^Kaplan--Meier method; ^Cox^Cox model.

[^5]: CI, confidence interval; dMMR, deficient mismatch repair; pMMR, proficient mismatch repair; FP, fluoropyrimidine; MT, mutated; WT, wild type.

[^6]: Multivariable Cox models were fitted on all patients, and subgroups of patients as indicated. All models were adjusted by age, gender, PS, T-stage, N-stage, tumor location, histological grade, KRAS and years to progression. The median survival after recurrence and HRs were only reported for MMR and BRAF variables.

[^7]: Likelihood-ratio test.
